CML66在肾癌组织中的表达及其临床意义

Expression of CML66 in renal carcinoma and its clinical significance

目的探究慢性粒细胞白血病肿瘤抗原66(CML66)在肾肿瘤组织中的表达及其临床意义。方法采用免疫组化法检测155例肾癌组织及其癌旁正常肾脏组织、36例肾血管平滑肌脂肪瘤组织中CML66蛋白的表达,分别比较肾癌组织与癌旁正常肾脏组织、肾血管平滑肌脂肪瘤组织的CML66阳性表达率,并分析肾癌组织CML66阳性表达率与临床特征的关系。结果肾癌组织中CML.66阳性表达率为83.9%,明显高于癌旁正常肾脏组织的35.5%(P<0.05);但与肾血管平滑肌脂肪瘤组织的80.6%比较,差异无统计学意义(P>0.05)。肾癌组织病理分级Ⅲ、Ⅳ级,临床分期Ⅲ、Ⅳ期的CML66阳性表达率均分别高于Ⅰ、Ⅱ级/期,差异均有统计学意义(P<0.05)。结论 CML66在肾癌组织中高表达有助于明确诊断,可作为评估肾癌病理分级、临床分期的指标,可能对肾癌术后辅助治疗有一定的参考价值。

Objective To investigate the expression of CML66 in renal carcinoma and its clinical significance. Methods The expression of CML66 in 155 samples of renal cell carcinoma and its adjacent normal tissue and 36 samples of renal angiomyolipoma were detected by immunohistochemical method. The relationship between CML66 expression and clinical charactenristics of renal cell carcinorma was analyzed. Results The positive expression rates of CML66 in renal cell carcinoma was 83.9%, significantly higher than the adjacent normal renal tissue （P〈0.05）, but there was no significant difference in CML66 expression between renal cell carcinoma and renal angiomyolipoma （P 〉0.05）. The positive expression rates of CML66 in renal cell carcinoma of pathological grade and clinical stages Ⅲ/Ⅳ were significantly higher than those in grade Ⅰ/ Ⅱ renal carcinoma （P〈0.05）, Conclusion Overexpression of CML66 may be used as an indicator for diagnosis of renal cell carcinoma and evalua- tion of pathological grade and clinical stages.